Krikorian Lazarus, an officer at Cencora, Inc., has reported the sale of 986 shares of the company's common stock. The transaction occurred on October 1, 2026, and was filed with the SEC on October 5, 2026. This event is significant as it highlights the ongoing financial activities within the company and the wholesale drugs industry.
Cencora, Inc. is classified under the Standard Industrial Classification for wholesale drugs, specifically dealing with proprietary drugs and druggists' sundries. The company is based in Conshohocken, Pennsylvania, and operates under the trading symbol COR. Recent SEC filings indicate that Lazarus has been active in trading shares, with this being the latest in a series of transactions.
The filing reveals that Lazarus sold his shares at a price of $303.18 each, totaling a transaction value of approximately $299,000. Following this sale, he retains ownership of 15,183 shares in Cencora, demonstrating his ongoing commitment to the company. The filing states, "Transaction Code: D" indicating a disposition of shares.
This transaction may affect various stakeholders, including investors and analysts monitoring Cencora's stock performance. The sale of shares by an officer can often signal changes in confidence or strategy within the company, though the specific implications of this sale are not detailed in the filing.
Looking ahead, the filing does not specify what happens next regarding further transactions or company developments. Investors and market analysts will likely keep a close eye on Cencora and its leadership as they navigate the competitive landscape of the wholesale drug industry.